(Total Views: 399)
Posted On: 11/03/2019 1:27:18 PM
Post# of 155843
Also, we had Dr. Burger as an option they could have went with, he had lots of CEO experience., but yet NP is still CEO.
Wash.-- CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced the appointment of Denis R. Burger, Ph.D. to its Board of Directors effective February 7, 2014. Dr. Burger is a life sciences executive with over 25 years of extensive scientific, operational and financial experience in the biotech industry.
As CEO or chairman of several biotechnology companies, Dr. Burger has led numerous corporate financing transactions and public securities offerings and has experience leading R&D, GMP manufacturing and clinical development functional areas. Additionally, he holds a patent for a method of detecting AIDS virus infection and oversaw the development of the first monoclonal antibody approved by the FDA for clinical use. Dr. Burger joins CytoDyn’s board as the Company prepares to advance the clinical development of PRO 140, a leading monoclonal antibody for the treatment of HIV.
Wash.-- CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced the appointment of Denis R. Burger, Ph.D. to its Board of Directors effective February 7, 2014. Dr. Burger is a life sciences executive with over 25 years of extensive scientific, operational and financial experience in the biotech industry.
As CEO or chairman of several biotechnology companies, Dr. Burger has led numerous corporate financing transactions and public securities offerings and has experience leading R&D, GMP manufacturing and clinical development functional areas. Additionally, he holds a patent for a method of detecting AIDS virus infection and oversaw the development of the first monoclonal antibody approved by the FDA for clinical use. Dr. Burger joins CytoDyn’s board as the Company prepares to advance the clinical development of PRO 140, a leading monoclonal antibody for the treatment of HIV.
(0)
(0)
